JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 16 October 2009
Journal of Endocrinology (2009) In press
DOI: 10.1677/JOE-09-0271
© 2009 Society for Endocrinology
This Article
Right arrow Accepted manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dahlman-Wright, K.
Right arrow Articles by Zhao, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahlman-Wright, K.
Right arrow Articles by Zhao, C.

REVIEW

LXR in cholesterol metabolism

Karin Dahlman-Wright and Chunyan Zhao

K Dahlman-Wright, Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden
C Zhao, Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

Correspondence: Karin Dahlman-Wright, Email: karin.dahlman-wright{at}biosci.ki.se

The liver X receptors (LXRs) are nuclear receptors that are activated by endogenous oxysterols, oxidized derivatives of cholesterol. There are two isoforms of LXR, LXRalpha (NR1H3) and LXRneta (NR1H2). Both LXRalpha and LXRbeta regulate gene expression by binding to DNA sequences associated with target genes as heterodimers with the retinoid X receptor (RXR) isoforms. LXRs act as cholesterol sensors: when cellular oxysterols accumulate as a result of increasing concentrations of cholesterol, LXR induces the transcription of genes that protect cells from cholesterol overload. In this review, we summarize the roles of LXRs in controlling cholesterol homoeostasis, including their roles in bile acid synthesis and metabolism/excretion, reverse cholesterol transport (RCT), cholesterol biosynthesis and uptake, and cholesterol absorption/excretion in the intestine. The overlapping and distinct roles of the LXRalpha and LXRbeta isoforms, and the potential use of LXRs as attractive targets for treatment of cardiovascular disease are also discussed.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the Society for Endocrinology.